Great Ormond Street Hospital for Children, Great Ormond Street, London, UK.
Pediatr Nephrol. 2012 Mar;27(3):357-62. doi: 10.1007/s00467-011-1872-3. Epub 2011 Apr 13.
Dyslipidemia has been shown to be a risk factor for increased cardiovascular morbidity and mortality in adult patients with chronic kidney disease (CKD) stages 2-4. In patients on dialysis, a paradoxical correlation has been found between low cholesterol values and increased mortality rates. No data exist in children. Treatment with statins has been convincingly shown to both reduce blood lipid levels and mortality rates from cardiovascular disease in adult patients in CKD stages 2-4. There is no strong literature support for treating patients on dialysis or after having had a transplant. Data on benefits of statin therapy do not exist in children with CKD. There are many differences between adult and paediatric kidney patients, and I caution on extrapolating the findings in adult patients to children. Studies are thus needed to evaluate the benefits and potential problems of statin treatment in children with CKD.
血脂异常已被证明是慢性肾脏病（CKD）2-4 期成年患者心血管发病率和死亡率增加的一个危险因素。在透析患者中，胆固醇值低与死亡率增加之间存在一种矛盾的相关性。在儿童中尚无数据。他汀类药物治疗已被充分证明可降低 CKD 2-4 期成年患者的血脂水平和心血管疾病死亡率。对于透析患者或移植后患者的治疗，目前没有强有力的文献支持。在 CKD 儿童中，他汀类药物治疗的益处数据也不存在。成人和儿科肾病患者之间存在许多差异，我警告不要将成人患者的发现推断到儿童身上。因此，需要进行研究来评估 CKD 儿童他汀类药物治疗的益处和潜在问题。
